<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679235</url>
  </required_header>
  <id_info>
    <org_study_id>2016-617</org_study_id>
    <secondary_id>188505</secondary_id>
    <nct_id>NCT02679235</nct_id>
  </id_info>
  <brief_title>Brain Energy and Aging With Triheptanoin</brief_title>
  <acronym>BEAT7</acronym>
  <official_title>Brain Energy and Aging With Triheptanoin: The BEAT7 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fonds de la Recherche en Santé du Québec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BEAT7-001 is a single group study (supplementation). Using a multi-modal brain imaging
      portfolio, this study will assess whether brain energy metabolism (glucose and ketones),
      structure or functional connectivity change in older people with frontal glucose
      hypometabolism after 28 days on an oral dose of 1 g/kg/day of triheptanoin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The participant will receive THN treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global change in brain glucose uptake</measure>
    <time_frame>28±2 days</time_frame>
    <description>18F-FDG PET scans</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Global change in brain ketone uptake</measure>
    <time_frame>28±2 days</time_frame>
    <description>11C-acetoacetate PET scans</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in brain volumes</measure>
    <time_frame>28±2 days</time_frame>
    <description>Structural imaging by T1-weighted MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in seed-based correlation maps</measure>
    <time_frame>28±2 days</time_frame>
    <description>Brain connectivity by RS-fMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in integrity of brain white matter tracts</measure>
    <time_frame>28±2 days</time_frame>
    <description>Fiber-bundle segmentation and fiber tractography by diffusion-weighted MRI (HARDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in global cognitive score</measure>
    <time_frame>28±2 days</time_frame>
    <description>Montreal Cognitive Assessment (score /30 points)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Frontal Lobe Hypometabolism</condition>
  <arm_group>
    <arm_group_label>Triheptanoin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triheptanoin suppementation 1g/kg body weight for 28 days (dose gradually increased each week, starting at, 0.25, 0.5, 0.75 and then 1 g) separated in 4 doses (with eah meal and before night)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triheptanoin</intervention_name>
    <description>The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack.</description>
    <arm_group_label>Triheptanoin</arm_group_label>
    <other_name>THN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women ≥65 years old;

          -  Score ≥26/30 on the Montreal Cognitive Assessment; -≥10% lower brain glucose uptake in
             the frontal cortex as determined by PET imaging.

        Exclusion Criteria:

          -  Score &lt;26/30 on the Montreal Cognitive Assessment;

          -  Medications likely to affect the primary cognitive outcome;

          -  Medical or psychiatric conditions that could interfere with study participation
             (Peterson et al. 2005);

          -  Fasting plasma glucose ≥7.0 mM (to avoid recruiting diabetics or pre-diabetics, both
             of which are risk factors for cognitive impairment in older persons (Mortimer et al.
             2010) and also inhibit ketogenesis (Fukao et al. 2004);

          -  Clinically-significant gastro-intestinal disease/conditions;

          -  Clinically-significant liver disease/dysfunction : ALT ≥37 UI/L, AST ≥36 UI/L, Total
             bilirubin ≥26 μmol/L;

          -  Clinically-significant renal disease/dysfunction : creatinine ≥92 μmol/L, glomerular
             filtration rate &lt;60 ml/min/1.73 m2 or &gt;90 ml/min/1.73 m2;

          -  Clinically-significant cardiac disease/conditions;

          -  Clinically-significant abnormal coagulation laboratory results or coagulation
             disorders at screening;

          -  Poorly controlled dyslipidemia (total cholesterol ≥6.2 mmol/L or triglycerides ≥2.20
             mmol/L)

          -  Hypertension: ≥140/90 mmHg;

          -  Substance abuse;

          -  Already on MCT supplementation;

          -  Visual or hearing impairment impeding comprehension;

          -  Non-French speaking;

          -  Any condition with life expectancy less than 5 years;

          -  Institutionalized or intending to move out of area within 1 year;

          -  Participation in other intervention trials.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Cunnane, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mélanie Fortier, M.Sc.</last_name>
    <phone>819-780-2220</phone>
    <phone_ext>45252</phone_ext>
    <email>melanie.fortier2@usherbrooke.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian-Alexandre Castellano, Ph.D.</last_name>
    <phone>819-780-2220</phone>
    <phone_ext>45623</phone_ext>
    <email>Alexandre.Castellano@USherbrooke.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H4C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Fortier, MSc</last_name>
      <phone>819-780-2220</phone>
      <phone_ext>45252</phone_ext>
      <email>Melanie.Fortier2@USherbrooke.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

